Provided by Tiger Trade Technology Pte. Ltd.

Anixa Biosciences

3.71
+0.12003.34%
Pre-market: 3.800.0900+2.43%05:31 EDT
Volume:182.43K
Turnover:673.81K
Market Cap:126.23M
PE:-12.22
High:3.76
Open:3.64
Low:3.60
Close:3.59
52wk High:5.46
52wk Low:2.32
Shares:34.02M
Float Shares:31.87M
Volume Ratio:0.71
T/O Rate:0.57%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.3035
EPS(LYR):-0.3367
ROE:-71.97%
ROA:-41.91%
PB:8.72
PE(LYR):-11.02

Loading ...

Anixa reports updated survival data from Phase 1 lira-cel ovarian cancer CAR-T trial

Reuters
·
May 11

Anixa Biosciences Inc - No Dose-Limiting Toxicities, Icans, or Significant Crs Observed in First Three Dose Cohorts

THOMSON REUTERS
·
May 11

Anixa Biosciences Reports Updated Positive Survival Observations From Ongoing Phase 1 Trial of Lira-Cel Ovarian Cancer CAR-T Therapy

THOMSON REUTERS
·
May 11

Anixa Biosciences wins Mexican patent for breast cancer vaccine technology

Reuters
·
Apr 29

Anixa Biosciences Announces Issuance of Mexican Patent Covering Breast Cancer Vaccine Technology

THOMSON REUTERS
·
Apr 29

Anixa to present ovarian cancer CAR-T trial update at ISCT annual meeting

Reuters
·
Apr 22

Anixa CEO presents at RedChip Biotech Resurgence virtual investor conference

Reuters
·
Apr 09

Anixa Biosciences Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Apr 08

Anixa CEO cites positive Phase 1 data for breast cancer vaccine, ovarian CAR-T in interview

Reuters
·
Apr 06

BUZZ-U.S. STOCKS ON THE MOVE-Eli Lilly, Space stocks, Anixa Biosciences

Reuters
·
Apr 02

Anixa Biosciences announces agreement with Cytovance Biologics

TIPRANKS
·
Apr 01

Anixa advances breast cancer vaccine toward Phase 2 after positive Phase 1 data

Reuters
·
Apr 01

Anixa Biosciences Inc: Phase 1 Study Met Primary Endpoints, Showed Safety and Tolerability at Maximum Tolerated Dose

THOMSON REUTERS
·
Apr 01

Anixa Biosciences Advances Breast Cancer Vaccine Toward Phase 2 After Positive Phase 1 Results; Cytovance Selected for Cgmp Manufacturing

THOMSON REUTERS
·
Apr 01

Anixa Biosciences Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Mar 31

BRIEF-Anixa Biosciences Announces Presentation Of Its Ovarian Cancer Car-T Therapy Clinical Trial

Reuters
·
Mar 30

Anixa to present Phase 1 lira-cel ovarian cancer CAR-T trial update at SGO meeting

Reuters
·
Mar 30

Anixa Biosciences Announces Presentation of Its Ovarian Cancer CAR-T Therapy Clinical Trial at the Society of Gynecologic Oncology Annual Meeting on Women's Cancer

THOMSON REUTERS
·
Mar 30

We're Not Very Worried About Anixa Biosciences' (NASDAQ:ANIX) Cash Burn Rate

Simply Wall St.
·
Mar 25

Anixa CEO Amit Kumar discusses breast cancer vaccine and ovarian cancer CAR-T trial data on Water Tower Research podcast

Reuters
·
Mar 12